Page last updated: 2024-11-02

potassium chloride and Pre-Hypertension

potassium chloride has been researched along with Pre-Hypertension in 1 studies

Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.
potassium chloride : A metal chloride salt with a K(+) counterion.

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Vongpatanasin, W	1
Peri-Okonny, P	1
Velasco, A	1
Arbique, D	1
Wang, Z	1
Ravikumar, P	1
Adams-Huet, B	1
Moe, OW	1
Pak, CYC	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension[NCT01682837]			Phase 2	35 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

24-hour Average Diastolic Blood Pressure

The average diastolic blood pressure over a 24 hour period. (NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	79
Potassium Citrate Powder Phase	78
Potassium Chloride Powder Phase	78
Placebo Phase	80

24-hour Average Systolic Blood Pressure

This is the average systolic blood pressure over a 24 hour period. (NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	127
Potassium Citrate Powder Phase	127
Potassium Chloride Powder Phase	126
Placebo Phase	129

24-hour Urinary Calcium

(NCT01682837)
Timeframe: 4 weeks of treatment

Intervention	mg/day (Mean)
Potassium Magnesium Citrate Powder Phase	158
Potassium Citrate Powder Phase	148
Potassium Chloride Powder Phase	160
Placebo Phase	181

Carotid to Femoral Pulse Wave Velocity

(NCT01682837)
Timeframe: 4 weeks

Intervention	m/s (Mean)
Potassium Magnesium Citrate Powder Phase	8.7
Potassium Citrate Powder Phase	8.8
Potassium Chloride Powder Phase	8.7
Placebo Phase	8.9

Central Aortic Diastolic Blood Pressure

(NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	77
Potassium Citrate Powder Phase	76
Potassium Chloride Powder Phase	77
Placebo Phase	79

Central Aortic Systolic Blood Pressure

(NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	121
Potassium Citrate Powder Phase	125
Potassium Chloride Powder Phase	123
Placebo Phase	126

Office Diastolic Blood Pressure

(NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	81
Potassium Citrate Powder Phase	81
Potassium Chloride Powder Phase	80
Placebo Phase	81

Office Systolic Blood Pressure

(NCT01682837)
Timeframe: 4 weeks

Intervention	mmHg (Mean)
Potassium Magnesium Citrate Powder Phase	124
Potassium Citrate Powder Phase	125
Potassium Chloride Powder Phase	127
Placebo Phase	129

Serum C-terminal Telopeptide (CTX)

(NCT01682837)
Timeframe: 4 weeks

Intervention	ng/ml (Mean)
Potassium Magnesium Citrate Powder Phase	0.46
Potassium Citrate Powder Phase	0.46
Potassium Chloride Powder Phase	0.45
Placebo Phase	0.49

Trials

1 trial available for potassium chloride and Pre-Hypertension

Article	Year
Effects of Potassium Magnesium Citrate Supplementation on 24-Hour Ambulatory Blood Pressure and Oxidative Stress Marker in Prehypertensive and Hypertensive Subjects. The American journal of cardiology, 2016, Sep-15, Volume: 118, Issue:6 Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Citrate	2016